Mink Therapeutics Inc (INKT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mink Therapeutics Inc (INKT) has a cash flow conversion efficiency ratio of 0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-941.35K) by net assets ($-13.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INKT equity financing ratio to measure how much of total assets are equity-financed.
Mink Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Mink Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of Mink Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Mink Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mink Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chips&Media Inc
KQ:094360
|
0.065x |
|
Gmb Korea
KO:013870
|
0.023x |
|
Universal Electronics Inc
NASDAQ:UEIC
|
0.069x |
|
Linq Minerals Limited
AU:LNQ
|
-0.067x |
|
Phosco Ltd
AU:PHO
|
0.440x |
|
NextBoat Inc.
NYSE MKT:NXB
|
-1.990x |
|
Il Sung Const
KO:013360
|
-0.199x |
|
Edesa Biotech Inc
NASDAQ:EDSA
|
-0.201x |
Annual Cash Flow Conversion Efficiency for Mink Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Mink Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Mink Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-19.59 Million | $-9.56 Million | 0.488x | -44.12% |
| 2023-12-31 | $-18.06 Million | $-15.76 Million | 0.873x | -98.14% |
| 2022-12-31 | $-401.30K | $-18.87 Million | 47.014x | +8814.55% |
| 2021-12-31 | $23.78 Million | $-12.83 Million | -0.539x | -448.59% |
| 2020-12-31 | $-53.87 Million | $-8.34 Million | 0.155x | -62.37% |
| 2019-12-31 | $-36.33 Million | $-14.94 Million | 0.411x | -- |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more